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The possibility of directly observing arterial flow in vivo has
been the dream of scientists for centuries (Fig. 1), but more
than that, both noninvasive imaging of coronary flow and
measurement of flow reserve have been considered a chi-
mera.
The study by Hirata et al. (1), along with many other
similar reports published in the last four years (2–8), shows
that, using a simple bedside tool such as echocardiography,
the chimera can be turned from a frightening mythological
monster to a friendly companion of our work.
Hormones and the microcirculation: Does the “storm”
affect women’s hearts? Gender differences in vascular re-
activity have been postulated for years, and common expe-
rience teaches that difficult days during the menstrual cycle
are often associated with mood instability. Whether these
changes are due to a direct hormonal effect or to a
generalized microcirculatory instability involving the heart
and the brain is not known.
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The interaction between microvascular flow and sex
hormones is complex and incompletely understood. It is
supposed that the vascular tree is targeted by the cyclic
hormonal variations during the menstrual life and that
hormones influence peripheral vascular reactivity, as
endothelial-dependent vasodilation is clearly reduced during
the menstrual phase and after menopause (9–12). In fact,
microvascular involvement is often cited to explain cyclic
chest pain and positive stress tests in fertile women with
normal epicardial coronary arteries. In addition, estrogens
increase the ischemic threshold in premenopausal women
with coronary artery disease (13), and they attenuate coro-
nary reactivity in postmenopausal women with angina pec-
toris and normal coronary angiograms (14). The role of
progestins is still controversial (15,16), and their association
with estrogens to protect against vascular stiffness has
yielded conflicting results (17,18).
However, despite the previous belief that sex hormones
might play a protective role for cardiovascular disease, at
least for primary prevention (19,20), recent randomized
trials surprisingly showed no benefit of hormonal therapy
replacement for secondary prevention (21–24).
Focusing the target: From brachial to coronary arteries.
There has been considerable interest in the brachial artery as
a surrogate target to measure microvascular dysfunction.
The main reason for this interest is that this artery is very
easy to image by two-dimensional Doppler ultrasound
because of its proximity to the skin. The brachial artery has
been considered a mirror of other inaccessible arteries, and
it has been used to measure vascular reactivity during cyclic
hormonal phases and to evaluate the efficacy of hormone
replacement in postmenopausal women (10,13). Hormones
may affect endothelial and microvascular function both in
brachial and coronary circulation. However, these two
territories are very different in terms of flow pattern,
resistances, metabolism, receptor population and microvas-
cular architecture. In this view, the great merit of Hirata and
colleagues (1) was to abandon the surrogate target to focus
our attention on the real target, the coronary circulation.
Angle correction: Essential or superfluous? In most of
the studies dealing with noninvasive coronary Doppler, the
theta angle between the incident beam and direction of flow
is corrected. However, coronary flow reserve is not an
absolute measure, but rather is the ratio between hyperemic
and baseline flow velocity, and it is not affected by the actual
flow velocity. Therefore, angle correction during the study is
unnecessary because this additional maneuver may prolong
adenosine infusion and may potentially introduce a bias
when strong corrections are used.
Microvascular flow, coronary stenosis and the “magic
number.” Adenosine is the key drug to measure coronary
flow reserve, because it produces maximal arteriolar dilation
with little or no effect on the epicardial artery (25). Coro-
nary flow is the product of velocity multiplied by the
cross-sectional area of the vessel. Because the diameter of
the epicardial artery does not significantly change during
adenosine infusion (25), any change in velocity translates
into an increase in flow. In the absence of coronary stenosis,
as described by Hirata and colleagues (1), microvascular
dysfunction may reduce coronary flow reserve. The situation
is more complex in the presence of a flow-limiting stenosis,
which by definition establishes a new resistance to flow that
is considerably higher compared to that produced by the
microcirculation (4). In other words, the “stop” produced by
the stenosis is dominant, and microcirculatory dysfunction
can hardly affect the “magic number” of 2 or 2.5 that has
been adopted to detect significant coronary artery disease. In
addition, adenosine may not be the ideal drug to study pure
microvascular dysfunction because its potent dilating effect
probably overwhelms vasoconstriction due to other causes.
Acetylcholine is the ideal drug; unfortunately, it cannot be
used intravenously.
The “third dimension” of Doppler. Time and velocity are
the most commonly used parameters to extrapolate clinically
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useful data from Doppler spectra. However, there is a third
potentially useful but neglected piece of information in the
Doppler spectrum: the intensity of the reflected signal (3).
Doppler intensity is proportional to the number of scatterers
and is a measure of blood volume crossing the Doppler
sample volume. Doppler intensity can be used to detect
coronary vasomotion as it significantly decreases during
handgrip in patients with coronary artery disease while it
increases or remains unchanged in normals. Doppler inten-
sity, expressed in gray levels or decibels, may be imple-
mented in the velocity data to compensate for potential
changes in lumen diameter during adenosine infusion, due
to flow-mediated vasodilation (25).
The squaring of the circle: The posterior descending
artery. The left anterior descending coronary artery is at
our fingertips, and its flow reserve can be measured nonin-
vasively in virtually every patient without the need of a
contrast agent (4). Despite the prominent importance of
measuring anterior descending flow, the evaluation of other
coronary territories is desirable. As 95% of the infarctions
are either anterior or inferior, we have recently concentrated
on the posterior descending coronary artery regardless of its
origin from the right or circumflex coronary artery (7) (Fig.
2). In a preliminary survey, we have found it feasible to
measure resting flow velocity and coronary flow reserve in
75% and 50% of the patients, respectively. This lower
success rate compared to the left anterior descending coro-
nary artery depends on two main factors: 1) adenosine-
induced hyperventilation interferes more with posterior
than with anterior descending imaging; and 2) whereas the
anterior descending artery has a dedicated transducer, the
posterior descending artery is studied by a conventional
transducer. Therefore, the feasibility of imaging the poste-
rior descending artery can be improved in two ways: 1) the
use of specific A2A adenosine receptor agonists producing
Figure 1. John Marshall’s double microscope for viewing the circulation of
the blood (from Harris’s Lexicon Technicum, 1704, Figure 103, and W.B.
Carpenter, The Microscope and Its Revelation. 7th ed. London: J & A
Churchill, 1891;135–8.
Figure 2. Transthoracic color Doppler echocardiography. Imaging of the
posterior descending coronary artery arising from a dominant right coro-
nary artery. Panels A and B show the short axis (A) and long axis (B) color
Doppler imaging of the artery in the posterior interventricular groove.
Pusled Doppler (C) shows inappropriate flow acceleration at the site of a
50% posterior descending stenosis (D). Flow acceleration is a mechanism
to compensate for lumen loss and maintain normal flow at rest.
Figure 3. High-resolution transthoracic echocardiography by an 8-MHz
linear probe shows the short-axis of the distal left anterior descending
(LAD) coronary artery in the anterior interventricular groove.
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little or no hyperventilation (26); and 2) the design of
specific probes and software. Considering that A2A receptor
agonists are being tested in clinical trials (26), most of the
investment should be done by the ultrasound companies.
This money seems to be very little, compared with the huge
investments of computed tomography or magnetic reso-
nance imaging, but it may nevertheless produce an even
more accurate tool to study coronary flow pathophysiology.
Coronary morphology: Beyond function. High-frequency
transducers allow us to directly image in 2D the mid- and distal
tract of the left anterior descending coronary artery from the
chest (27) and to measure its cross-sectional area (Fig. 3). This
method has the potential to show plaque morphology and
measure coronary vasomotion and the effect of drugs on lumen
diameter. Finally, computerized transesophageal echocardiog-
raphy may allow reconstruction of long tracts of the coronary
arteries, with direct imaging of coronary lesions and stents
(Zotz, personal communication), and may potentially compete
with computed tomography and resonance imaging to detect
coronary atherosclerosis.
Conclusions. What was believed to be impossible yester-
day seems to be easy today. But the “impossible” can be
achieved only with effort, motivation and love. Echocardi-
ography is like the agile David sculptured by Bernini in the
Galleria Borghese; echocardiography can compete with the
giants of radiology, and will bring us very far in the
adventure of coronary flow imaging.
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